Oppenheimer Asset Management Inc. raised its position in Syneos Health Inc (NASDAQ:SYNH) by 83.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,314 shares of the company’s stock after buying an additional 1,510 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Syneos Health were worth $170,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Financial Gravity Wealth Inc. bought a new position in Syneos Health in the 2nd quarter valued at $29,000. AlphaOne Investment Services LLC boosted its holdings in Syneos Health by 29.0% in the 1st quarter. AlphaOne Investment Services LLC now owns 1,590 shares of the company’s stock valued at $82,000 after purchasing an additional 357 shares during the period. Smith Asset Management Group LP boosted its holdings in Syneos Health by 1,039.3% in the 2nd quarter. Smith Asset Management Group LP now owns 5,560 shares of the company’s stock valued at $284,000 after purchasing an additional 5,072 shares during the period. Bank of Montreal Can boosted its holdings in Syneos Health by 389.8% in the 2nd quarter. Bank of Montreal Can now owns 7,764 shares of the company’s stock valued at $397,000 after purchasing an additional 6,179 shares during the period. Finally, Campbell & CO Investment Adviser LLC boosted its holdings in Syneos Health by 7.5% in the 1st quarter. Campbell & CO Investment Adviser LLC now owns 8,301 shares of the company’s stock valued at $430,000 after purchasing an additional 582 shares during the period.

SYNH has been the subject of several analyst reports. UBS Group raised their price target on shares of Syneos Health from $53.50 to $57.00 and gave the company a “neutral” rating in a report on Thursday, August 29th. Zacks Investment Research downgraded shares of Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 price objective for the company. in a report on Tuesday. Credit Suisse Group lifted their price objective on shares of Syneos Health from $56.00 to $58.00 and gave the stock an “outperform” rating in a report on Friday, August 23rd. SunTrust Banks lifted their price objective on shares of Syneos Health to $68.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, KeyCorp lifted their price objective on shares of Syneos Health from $63.00 to $65.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $58.63.

Syneos Health stock traded up $0.22 during mid-day trading on Friday, hitting $54.57. The company’s stock had a trading volume of 6,697 shares, compared to its average volume of 374,914. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.89 and a quick ratio of 0.89. The stock has a market cap of $5.38 billion, a price-to-earnings ratio of 20.86, a price-to-earnings-growth ratio of 1.81 and a beta of 1.51. The business has a 50 day moving average price of $51.06 and a 200-day moving average price of $48.13. Syneos Health Inc has a 12 month low of $36.26 and a 12 month high of $56.34.

Syneos Health (NASDAQ:SYNH) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.02. Syneos Health had a net margin of 0.36% and a return on equity of 9.82%. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the previous year, the firm posted $0.62 earnings per share. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities research analysts expect that Syneos Health Inc will post 2.73 earnings per share for the current fiscal year.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Further Reading: Bar Chart

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.